Innovative first in class HSF1 pathway cancer drug shows strong results in new study 05 Apr 2023 A new, oral ‘first in class’ experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. Find out more Show/Hide
Innovative ICR-discovered drug to enter first clinical trial, targeting HSF1 pathway 26 Aug 2021 Cancer patients are set to receive, for the first time, a highly innovative investigational drug called NXP800 – which was discovered at The Institute of Cancer Research, London. Find out more Show/Hide